Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Heptares Therapeutics Raises US$21 Million In Series B Financing 12
Partnerships 13
Heptares Therapeutics Enters into Research Agreement with Juntendo University 13
Heptares Therapeutics and PeptiDream Enter into Agreement 14
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 15
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 16
Jitsubo Enters into Agreement with Heptares Therapeutics 17
Heptares Therapeutics and leadXpro Enter into Agreement 18
Heptares Therapeutics to Form Partnership with Kymab 19
Heptares Therapeutics Enters into Agreement with Pfizer 20
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 21
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 22
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 23
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 24
AstraZeneca Enters Into Co-Development Agreement With Heptares 25
Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharma 27
Licensing Agreements 28
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 28
Allergan Amends Licensing Agreement with Heptares Therapeutics 29
Teva Pharma Enters into Licensing Agreement with Heptares Therapeutics 30
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 31
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 32
Acquisition 34
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 34
Sosei Acquires Heptares Therapeutics for USD400 Million 35
Heptares Therapeutics Ltd – Key Competitors 36
Heptares Therapeutics Ltd – Key Employees 37
Heptares Therapeutics Ltd – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Government and Public Interest 39
May 31, 2017: Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 39
Dec 08, 2016: Heptares Scientists Solve Structure of CCR9 Chemokine Receptor Offering Unique Opportunity to Apply Structure-Based Design Across Chemokine Receptor Family 40
Dec 08, 2016: Sosei subsidiary Heptares scientists solve structure of CCR9 Chemokine receptor offering unique opportunity to apply structurebased design across Chemokine receptor 41
Apr 25, 2016: Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors Enabling Structure-based Design for Metabolic Disease 42
Jan 11, 2016: Tetragenetics Awarded $1.5M Research and Development Grant by NIH 43
Product News 44
May 31, 2017: Sosei Subsidiary Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 44
Clinical Trials 45
Apr 05, 2017: Heptares to Receive US$12 Million Milestone Payment from Astrazeneca 45
Jul 06, 2016: Initiation of Phase 1 Clinical Study With Novel Immuno-oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca 46
Feb 10, 2016: Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-in-class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia 47
Other Significant Developments 48
Feb 02, 2016: Heptares Launches “Orbit” Initiative – A New Collaborative Drug R&D Programme for Industry and Academia Focused on G Protein-Coupled Receptors (GPCRS) 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heptares Therapeutics Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Heptares Therapeutics Raises US$21 Million In Series B Financing 12
Heptares Therapeutics Enters into Research Agreement with Juntendo University 13
Heptares Therapeutics and PeptiDream Enter into Agreement 14
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 15
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 16
Jitsubo Enters into Agreement with Heptares Therapeutics 17
Heptares Therapeutics and leadXpro Enter into Agreement 18
Heptares Therapeutics to Form Partnership with Kymab 19
Heptares Therapeutics Enters into Agreement with Pfizer 20
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 21
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 22
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 23
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 24
AstraZeneca Enters Into Co-Development Agreement With Heptares 25
Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharma 27
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 28
Allergan Amends Licensing Agreement with Heptares Therapeutics 29
Teva Pharma Enters into Licensing Agreement with Heptares Therapeutics 30
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 31
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 32
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 34
Sosei Acquires Heptares Therapeutics for USD400 Million 35
Heptares Therapeutics Ltd, Key Competitors 36
Heptares Therapeutics Ltd, Key Employees 37
Heptares Therapeutics Ltd, Subsidiaries 38